Cholesterol-dependent complement activation has been proposed as a factor that might influence the pathogenesis of atherosclerosis. Although antibodies to cholesterol conjugates have been reported, cholesterol is widely regarded as a poorly immunogenic substance. Monoclonal IgM complement-fixing antibodies to cholesterol were obtained in the present study after immunizing mice with liposomes containing high amounts of cholesterol (71 mol % relative to phosphatidylcholine) and lipid A as an adjuvant.
Cholesterol has been widely studied as a fundamental and ubiquitous constituent of cell membranes and lipoproteins (1, 2) . Despite occasional reports that conjugates of cholesterol can be immunogenic (3) (4) (5) , because of its widespread distribution and important biological roles cholesterol has generally been assumed to be a nonimmunogenic or poorly immunogenic molecule. However, since 1977 several laboratories have reported activation of the classical and alternative pathways of complement by cholesterol (6) (7) (8) (9) (10) (11) . The exact mechanism (or mechanisms) of complement activation by cholesterol has not been determined. In one case human IgG antibodies to cholesterol were implicated in the activation of the classical pathway (9) . On the other hand, it has been proposed that nonimmune activation of the alternative pathway of rabbit complement (7) or human complement (8, 9 ) also occurs. The issue of the immunogenicity of cholesterol is an important one, since antibodies to cholesterol have been reported to protect against induced atherosclerosis in rabbits (4) . On the other hand, activation of the classical pathway of complement by cholesterol has been proposed as a possible mechanism in the pathogenesis of atherosclerosis (6, 9, 11) .
In previous studies we induced antibodies to the phospholipid constituents of lipid model membranes (liposomes) (reviewed in ref. 12 ). Production of antibodies to liposomes was achieved by utilizing lipid A as a powerful adjuvant in the liposomal lipid bilayer. In the present work we used lipid A as an adjuvant to induce antibodies to liposomes containing high concentrations of cholesterol. We found that cholesterol is an excellent immunogen and that murine monoclonal antibodies to cholesterol are easily obtained.
MATERIALS AND METHODS
Liposomes. The liposomal lipids consisted of combinations of dimyristoyl phosphatidylcholine ([Myr2]PtdCho) (Calbiochem-Behring), cholesterol, dicetyl phosphate (Cet2-P) (K & K Laboratories, Fairview, NJ), and lipid A (isolated from Escherichia coli 0-111 as described in ref. 13) . Different batches of reagent-grade cholesterol received from several suppliers were not completely "pure" and had melting points ranging from 118'C to 1450C. After recrystallization three times from hot ethanol, the published melting point (1480C) was achieved. The effectiveness of the cholesterolpurification procedure was further manifested by the fact that when tested as an antigen by ELISA (see below), after each of the recrystallizations the cholesterol showed progressively improved antigenic activity. When fully purified cholesterol was examined by thin-layer chromatography, only a single spot was present and a contaminant sometimes found in unpurified cholesterol (25-hydroxycholesterol) was not detected. Complete details on the sources of lipids and preparation of liposomes (multilamellar vesicles) have been given previously for liposomes in general (13) and highcholesterol liposomes in particular (6) (6, 13) .
Complement-Dependent Immune Assay. Complementdependent immune damage to liposomes resulting in release of trapped liposomal glucose has been described in detail (6, 13) . Glucose released from liposomes by the action of complement was measured spectrophotometrically by using a Tris-buffered assay reagent containing hexokinase, glucose-6-phosphate dehydrogenase, ATP, and NADP.
Enzyme-Linked Immunosorbent Assay (ELISA). ELISAs were performed by using crystalline cholesterol as an antigen on the bottoms of the wells of microtiter plates (13) . The ELISA procedure was developed by modification of previous techniques for analysis of antibody binding to lipid antigens (14) (15) (16) . Crystalline cholesterol was coated onto the surface of wells in polystyrene plates (Immulon 96, "U" bottom, Dynatech Laboratories, Alexandria, VA) by addition of an ethanolic solution and evaporation of the solvent by air under a fume hood. Plates were further dried under high vacuum and stored at -30'C when not used the same day. Plates were blocked by addition of phosphate-buffered saline (PBS: 137 mM NaCI/2.7 mM KCI/9.6 mM phosphate, pH 7.2) containing 10%o heat-inactivated fetal bovine serum (FBS) (M.A. Bioproducts, Walkersville, MD). This was accomplished by washing the wells three times for 10 min each. Fifty microliters of ascites fluid containing monoclonal antibodies, diluted in PBS containing 10% FBS, was added to the wells and incubated 1 hr at room temperature. Plates were then washed three times for 5 min each with PBS. Fifty microliters of goat anti-mouse IgM (.L chain) alkaline phosphase conjugate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) at 1 ,ug/ml in PBS containing 10%6 FBS was added to the wells and incubated 1 hr at room temperature. Plates were again washed three times for 5 min each with PBS. Fifty microliters of the substrate, p-nitrophenyl phosphate at 2 mg/ml in diethanolamine buffer (Kirkegaard and Perry Laboratories) was added to the wells and incubated 30 min at room temperature. Plates were scanned for optical activity at 405 nm using a Titertek Multiscan (Flow Laboratories). Values reported were adjusted by subtracting values in blank wells that lacked both antigen and monoclonal antibody.
Immunoelectron Microscopy. A cholesterol crystal suspension was prepared by sonicating cholesterol crystals (20 mg/ml) in PBS containing 0.5% fetal calf serum (FCS) (GIBCO). Aliquots (200 , ul) were placed into plastic centrifuge tubes and subjected to the following procedure. For each wash the tubes were centrifuged for 3 min in a Beckman Microfuge B, the supernatant was removed, 150 1,l of wash buffer was added, and the tube was agitated on a Vortex to resuspend the pellet. The cholesterol crystals were washed once with PBS, resuspended in PBS with 10%o FCS for 30 min at room temperature, and washed once with PBS containing 10o FCS.
The crystals were resuspended for 1 hr at room temperature in a 1:5 dilution of ascites fluid containing murine anti-cholesterol antibody and then washed three times with PBS containing 10% FCS. They were then resuspended with affinity-purified secondary antibody, consisting of 10-nmgold-labeled goat anti-mouse IgM (Janssen Life Science, Piscataway, NJ) diluted 1:10, for 1 hr at room temperature.
The crystals were subsequently washed three times with PBS containing 10% FCS. (Fig. 2) . Al when only complement was present, no significant immune damage occurred (Fig. 2) . Binding of Antibodies to Crystalline Cholesterol. A solidphase ELISA was developed for detecting IgM immunoreactivity with crystalline cholesterol, and each of four anticholesterol antibody clones showed positive results (Fig. 3) . Two of the four antibodies (nos. 1 and 2) were still easily detected even when diluted 1:31,250. Antibody no. 3 had the lowest activity both in the glucose-release assay (Fig. 1) and in the ELISA (Fig. 3) . As with the two other immunoassays, the control ascites fluid containing IgM antibody to trypanosomal glycoprotein (32.2A6.1) failed to show reactivity in the ELISA.
The binding of monoclonal anti-cholesterol antibodies to cholesterol crystals was clearly demonstrated also by electron microscopy using a two-step labeling technique. After incubation of the cholesterol-crystal suspension with the anti-cholesterol antibody, followed by a secondary antibody conjugated to colloidal gold, gold particles were observed dispersed over the surface of the crystals (Fig. 4a) . Gold particles were absent from the surface of cholesterol crystals treated with control ascites fluid containing antibody to trypanosomal glycoprotein (Fig. 4b) . Gold particles were absent also in control experiments (data not shown) in which the cholesterol crystals were treated with the secondary antibody but not with the primary (anti-cholesterol) antibody.
Separate experiments confirmed that affinity-purified anticholesterol antibodies (see Materials and Methods) gave strongly positive results when tested with crystalline cholesterol either by ELISA or by the immunoelectron microscopy technique.
DISCUSSION
Complement fixation by cholesterol has been previously reported but the complement-activating mechanisms involved (immune or nonimmune) have not been fully clarified (6) (7) (8) (9) (10) (11) . Activation of complement by cholesterol has been proposed as a mechanism in the pathogenesis of atherosclerosis (6, 9, 11) . However, the immunogenicity of cholesterol itself has not been definitively addressed, and cholesterol often has been assumed to be a nonimmunogenic substance. Antibodies to cholesterol have been reported to occur after immunizing with cholesterol-albumin conjugates (3, 4) or with a synthetic phospholipid, phosphatidylcholesterol (5) . Rabbits that were immunized with cholesteryl ester-albumin conjugates were resistant to development of atherosclerotic plaques induced by cholesterol feeding (4). Despite these observations, the ability to produce complement-fixing antibodies to cholesterol has not been widely recognized. The present study demonstrates that when cholesterol is placed in the proper environment it is a highly immunogenic molecule. Cholesterol therefore joins a growing list of lipids that were previously thought to be nonimmunogenic but are now known to be excellent immunogens (12, 19) .
Three conclusions from our data are particularly noteworthy. First, the antibodies to cholesterol exerted considerable specificity for the high-cholesterol (71% cholesterol) liposomes used for immunization. Antibodies were originally selected for the absence of detectable crossreactivity with liposomes having "low" cholesterol (43% cholesterol or less) (Figs. 1 and 2) . It is evident therefore that above 50 mol %, cholesterol entered into a separate phase in the liposomes that allowed it to become an immunodominant molecule. Second, the induction of antibodies to cholesterol was achieved by utilizing lipid A, the endotoxic moiety of Gramnegative bacterial lipopolysaccharide, as a powerful adjuvant in the liposomes. In the absence of lipid A the liposomes were not immunogenic. The requirement for endotoxin (lipid A) for stimulation of antibodies to cholesterol is consistent with a previous hypothesis that "naturally occurring" antibodies (often present in normal serum) that react with constituents of lipid bilayers are induced by endotoxin (20, 21) . Third, high titers of antibodies were readily induced within 3 days after a single primary immunization, and when A.
- the spleens were removed and fused with myeloma cells to produce hybridomas, at least 70% of the fused splenic cells were secreting complement-fixing antibodies to cholesterol. The exact configuration of the cholesterol that was being recognized by the antibodies in the 71% cholesterol compared to 43% cholesterol liposomes is unknown. There has been considerable discussion in the literature on the biophysical, biochemical, and morphological properties of liposomes containing high concentrations of cholesterol. It is well established that liposomes (22) (23) (24) (25) or even cells (26) can have cholesterol/phospholipid ratios of 2:1, or even up to 4:1, and 71% cholesterol liposomes have a cholesterol/ phospholipid ratio of 2.5:1. Liposomes having cholesterol/ phospholipid ratios >2:1 are in a nonequilibrium metastable state in which cholesterol gradually separates over a course of days or weeks into a different phase from the phospholipid (25) . Electron microscopic studies have suggested that crystalline cholesterol may be associated with, and even slowly "grow from," high-cholesterol multilamellar liposomes.
Although it is premature at this juncture to identify a structure of liposomal cholesterol that is recognized by the antibody, there is ample precedent for exquisite discrimination of unique lipid patterns by antibodies to lipids and liposomes (12, 27) . For example, specificities of individual antibodies to phosphatidylinositol phosphate were identified that either did or did not crossreact with phosphatidylinositol or phosphatidylinositol bisphosphate (28) . Monoclonal antibodies to cardiolipin can react with cardiolipin or even phosphatidylethanolamine in the hexagonal HI, phase, but not with the lipids in the bilayer configuration (29) . Recently it was shown that the TEPC 15 IgA myeloma antibody, which binds to phosphocholine but also recognizes phosphatidylcholine (30) , interacts differently with phosphatidylcholine and phosphatidylethanolamine in a lipid monolayer system (31) .
Despite the ability to discriminate between unique lipid patterns, all of our anti-liposome antibodies, including antibodies to cholesterol, have a "subsite" that can recognize soluble phosphorylated haptens in the antibody binding site (12) . It has been postulated that the phosphate-binding subsite might be responsible for some of the crossreactivity that is sometimes observed between antibodies to DNA and antibodies to cardiolipin (12) . Although some of our monoclonal antibodies to liposomes do react by ELISA with purified lipid A, none of the monoclonal antibodies that recognize lipid A react with purified cholesterol.
The observations in the present paper have several implications. They support the hypothesis that activation of complement by antibodies to cholesterol could play a role in the pathogenesis of atherosclerosis. Furthermore, activation of complement could be restricted specifically only to those sites that have high accumulations of crystalline cholesterol where cholesterol may serve as an immunodominant epitope. This provides a theoretical basis for the previous proposal (6, 9, 11) that complement activation by crystalline cholesterol might serve as a potential amplifier of atherosclerotic ischemic damage. This latter suggestion was supported by the clinical observation that an IgG antibody apparently was reacting specifically with crystalline cholesterol and activating the classical pathway of complement in a patient with ulcerating atherosclerosis (9) . Based on our previous successful experience in stimulating antibodies to other types of lipids, it is likely that lower concentrations of membrane cholesterol also could modulate the reactivities of antibodies having specificities to other lipid bilayers having different immunodominant epitopes (12, 19) .
